Oracle (Redwood Shores, CA) announced the release of Remote Data Capture 4.6. The company collaborated with customer advisors to develop additional functions for the EDC application. The latest additions include scalability improvements, flexible branching to support complex trial design (including for oncology trials), access restriction capabilities, and patient management enhancements.
Remote Data Capture is integrated with the company’s clinical data management system, Oracle Clinical.
“R&D efficiency, clinical effectiveness and time to market continue to be the greatest challenges facing life sciences organizations today,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences, in a company press release. “Oracle Remote Data Capture 4.6 provides strong evidence of our unwavering commitment to helping clinical trial sponsors and CROs accelerate insights for better health, and will enable our customers to complete clinical trials significantly faster and much more cost effectively than ever before.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.